Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIP floxuridine after resection of colorectal liver metastases
2016-004299-24Phase 2Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Erasmus MC Cancer Institute. Primary endpoints: 90-day postoperative complications and Successful administration of at least one HAIP chemotherapy cycle. Started May 2017; status: active.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2016-004299-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004299-24.